Salmeterol/flutikazon Cipla 25 mikrograma + 250 mikrograma u jednoj dozi, stlačeni inhalat, suspenzija
| Name | Salmeterol/flutikazon Cipla 25 mikrograma + 250 mikrograma u jednoj dozi, stlačeni inhalat, suspenzija |
|---|---|
| Former Name | Salmeterol/flutikazonpropionat Momaja 25 mikrograma + 250 mikrograma u jednoj dozi, stlačeni inhalat, suspenzija |
| Marketing Authorisation Number | HR-H-705296771 |
| Active Substance | salmeterolksinafoat flutikazonpropionat |
| Composition | svaki pojedinačni potisak salmeterol i flutikazonpropionat stlačenog inhalata, suspenzije sadrži: 25 mikrograma salmeterola (u obliku salmeterolksinafoata) i 250 mikrograma flutikazonpropionata (ispuštenih iz ventila) |
| Pharmaceutical Form | stlačeni inhalat, suspenzija |
| Manufacturer | S&D Pharma CZ, spol. s r.o, Pchery (Pharmos a.s. facility), Češka Orion Corporation, Orion Pharma, Espoo, Finska Orion Corporation, Orion Pharma, Salo, Finska Cipla Europe NV, Antwerpen, Belgija |
| Marketing Authorisation Holder | Cipla Europe NV, De Keyserlei 60C, Bus 1301, Antwerpen, Belgija |
| Marketing Authorisation Date | 12.05.2020 |
| MA Period of Validity | unlimited |
| Classification Number | UP/I-530-09/18-02/310 |
| Registration Number | 381-12-01/70-20-04 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | Medicinal product on medical prescription for renewable delivery |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | R03AK06 |
| Marketing status | Marketed |
| Shortage status | Actual |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
